Research Article

Osteoarthritic Patients

Journal of Ayurveda and Integrated Medical Sciences

2024 Volume 9 Number 3 March

Evaluation of efficacy of topical herbal analgesic Arthrella Ointment in Osteoarthritic Patients

Mote D1*

1* Dnyaneshwar Mote, Md Ayu, Registration No. I-47665-A Vidnyanam Clinic, Kings Building Katraj-Kondhwa Road Katraj, Pune, Maharashtra, India.

Osteoarthritis (OA) is a chronic condition involving degradation of cartilage within the joints mostly found in Elderly population causing immense pain and disability in Patients, NSAIDs are the first line of drug in conventional medicine to manage pain. But it leads to Gastrointestinal, Cardiovascular, Renal and other systemic AEs. Arthrella Ointment being a Topical-Herbal ointment has no reported side effects and AEs. Thus, a safe treatment option to alleviate pain in OA Patients. In this Clinical study 87 Subjects with OA were divided in two groups, one was treated with Arthrella Ointment for 4 weeks and results were compared with Placebo Control Group. The result showed better WOMAC and VAS scores after 4 weeks along with statistically significant difference in the relief of pain in the two groups. This effect increased regularly over the whole study period. There were no adverse reactions attributed to the Arthrella ointment. Thus, it was concluded that Arthrella Ointment is effective in pain management Associated with OA without any AEs and Side Effects.

Keywords: Arthrella Ointment, Osteoarthritis (OA), WOMAC, VAS scores

Corresponding Author How to Cite this Article To Browse
Dnyaneshwar Mote, Md Ayu, Registration No. I-47665-A Vidnyanam Clinic, Kings Building Katraj-Kondhwa Road Katraj, Pune, Maharashtra, India.
Mote D, Evaluation of efficacy of topical herbal analgesic Arthrella Ointment in Osteoarthritic Patients. J Ayu Int Med Sci. 2024;9(3):1-5.
Available From

Manuscript Received Review Round 1 Review Round 2 Review Round 3 Accepted
2024-01-17 2024-01-27 2024-02-07 2024-02-17 2024-02-26
Conflict of Interest Funding Ethical Approval Plagiarism X-checker Note
None declared Nil Yes 20.75

© 2024by Mote Dand Published by Maharshi Charaka Ayurveda Organization. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/ unported [CC BY 4.0].


Osteoarthritis (OA) is a chronic condition involving degradation of cartilage within the joints. It is the most common form of arthritis and is prevalent in elderly people. It is associated with pain, substantial disability and quality of life is hampered due to mobility limitations.[1,2]

Oral therapies for patients with mild to moderate OA pain include paracetamol (acetaminophen) and NSAIDs which are associated with dose, duration and age-dependent risks of gastrointestinal, cardiovascular, renal, hematological and hepatic adverse events (AEs), as well as clinically meaningful drug interactions.[3,9] Topical therapies present a valuable therapeutic option for OA pain management. They provide an alternative to oral medications for patients trying to get relief from arthritis pain.[10] Topical medications target the site of application and ideally produce effective drug concentrations locally with minimal systemic absorption and help in periarticular pain associated with OA.[11]

Drug description

Arthrella Ointment is a Topical Herbal analgesic ointment designed for the treatment of pain associated with Osteoarthritis, rheumatoid arthritis, cervical spondylosis, frozen shoulder, sprains, sport injuries and myalgia. It has analgesic, anti-inflammatory, antioxidant, counterirritant properties.[12] Active Herbal Ingredients in Arthrella ointment induce vasodilation, increases blood circulation and a feeling of warmth.[12] Gaultheria fragrantissima, Eucalyptus globulus and Cinnamomum camphora work synergistically to reduce muscular pain, joint swelling, joint tenderness and joint stiffness and help improve range of movement of the affected joints. [13,15]

In the present study, the efficacy and safety of Arthrella Ointment supplied by M/S Charak Pharma Pvt. Ltd., in the symptomatic alleviation of acute and chronic inflammatory Osteoarthritis pain was evaluated.

Materials and Methods

Study design

A placebo-controlled randomized double-blind single center clinical trial was conducted

for one month. All patients gave written informed consent before randomization between Arthrella Ointment and placebo ointment groups.

Patients were recruited with the following inclusion and exclusion criteria

Inclusion criteria

  • Age 40 - 80yrs of either gender
  • Osteoarthritis diagnosis according to clinical history and X-ray
  • Maximum visual analog score for pain on movement, between 40 - 80yrs.
  • Successful completion of treadmill walking test

Exclusion criteria

  • Patients with history of alcohol or drug abuse concomitant skin disease or abrasions at the application site
  • Usages of any other topical product at the application site were excluded from the study.
  • Pregnant and lactating women were also excluded from the study.

Study procedure

A total of 87 Osteoarthritis human subjects, suffering from acute and chronic inflammatory pain, were included in the study. 8 patients dropped out of the study. After screening, the subjects were randomly assigned to two groups (n = 38 for placebo ointment and n= 41 for Arthrella Ointment).

All the patients were advised to apply a small quantity of Arthrella Ointment topically to the affected region, with gentle massage, twice daily for one month. All the patients were assessed for the muscular pain, joint swelling, joint tenderness, early morning joint stiffness and joint pain.

The primary efficacy variable was total WOMAC score that was modified for the target population. The index consists of 24 questions (5 pains, 2 stiffness, and 17 physical functions). Visual analog score (VAS) was used to assess pain and 6 minute walking test was performed. Patient diaries and consultations with physicians were used to determine progress at baseline, and then 2nd and 4th week. At the baseline visit, vital signs were assessed and tests were performed. All the patients

were assessed for local adverse reactions like irritation, burning/stinging sensation and erythema.

Follow up was taken weekly and the WOMAC and VAS score evaluation was done during each week follow-up visit. All the adverse events either reported or observed by the patients were recorded with information about severity.

Subject demographics enrolled in the clinical trial are summarized in table 1. Randomization was effective with characteristics being indistinguishable between the two groups. Baseline Pain efficacy measures in the two groups are summarized in table 2. There was no statistical difference between groups.

Table 1: Subject demographic characteristics

Demographic CharacteristicsArthrella Ointment (n=41)Placebo ointment (n=38)
Age (years)53.1 ± 8.954.1 ± 7.7
Gender (F:M)22:1926:12
BMI26.5 ± 3.326.5 ± 3.1

Results expressed as mean ± SD. There was no statistical difference between groups.

Table 2: Baseline Pain efficacy measures

Baseline measuresArthrella Ointment (n=41)Placebo ointment(n=38)
WOMAC-Pain7.3 + 3.36.6 + 3.4
WOMAC-Stiffness2.8 + 1.52.8 + 1.8
WOMAC-Physical Function29.5 + 12.425.4 + 11.4
WOMAC Total39.6 + 13.434.8 + 15.8
VAS Pain59.5 + 10.063.2 + 10.0


Efficacy in total WOMAC score

In this trial a steady reduction in total WOMAC with placebo treatment over the 4 weeks trial period was evident. However, reductions in total WOMAC were significantly greater with Arthrella ointment treatment (Table 3). This was noted from 2nd week of treatment with Arthrella ointment.

Table 3: Efficacy in total WOMAC score

WOMAC TotalBaseline valueAfter Treatment
2nd week4th week
Arthrella ointment (n=41)39.6 + 13.428.5 + 10.118.2 + 8.9
Placebo ointment (n=38)34.8 + 15.834.3 + 15.232.6 + 11.2

Similar to total WOMAC, assessments for pain, stiffness and physical function indicated that Arthrella ointment was significantly more effective than placebo. Arthrella ointment resulted in significantly greater improvements than placebo ointment for all measures (Table 4).

Table 4: Assessments for pain, stiffness and physical function

WOMAC-PainBaseline valueAfter Treatment
2nd week4th week
Arthrella ointment (n=41)7.3 + 3.36.2 + 4.34.5 + 1.2
Placebo (n=38)6.6 + 3.46.4 + 1.65.9 + 4.5
Arthrella ointment (n=41)2.8 + 1.52.1 + 0.51.4 + 0.2
Placebo (n=38)2.8 + 1.82.6 + 0.72.4 + 0.2
WOMAC-Physical Function
Arthrella ointment (n=41)29.5 + 12.420.2 + 10.912.3 + 9.8
Placebo (n=38)25.4 + 11.425.3 + 12.324.3 + 11.2

Efficacy in VAS Pain

Pain, assessed with a visual analog scale, was indistinguishable at baseline between groups: placebo ointment 63.2 + 10.0; Arthrella ointment 59.5 + 10.0. VAS pain was reduced with Arthrella ointment treatment over the 4th week study period (Table 5). The benefits were significantly greater with Arthrella ointment.

Table 5: Efficacy in VAS Pain

VAS PainBaseline valueAfter Treatment
2nd Week4th week
Arthrella ointment (n=41)59.5 + 10.041.2 + 4.332.5 + 1.2
Placebo (n=38)63.2 + 10.060.4 + 1.659.9 + 4.5

There were no clinically significant adverse reactions (either reported by the patients, or observed by the investigators), and the overall compliance to the treatment was excellent.


Osteoarthritis is the leading cause of disability with about 240 million people affected worldwide.[16] Age is a major risk factor and the limitations on physical performance and concomitant pain results in osteoarthritis being a major social burden.[1,3] Despite this burden and the high incidence of osteoarthritis there has been little in the way of treatments that modify the disease course and alleviate symptoms.

Topical administration of anesthetics and analgesics

can allow for the efficient, painless delivery of medications that may reduce systemic side effects associated with the medication while providing clinical advantages over injected or oral administration for the same clinical situation.[12]

The present clinical study was planned to study the efficacy and safety of Arthrella ointment in the symptomatic alleviation of acute and chronic inflammatory Osteoarthritis pain. The result showed better WOMAC and VAS scores after 4 weeks along with statistically significant difference in the relief of pain in the two groups. This effect increased regularly over the whole study period. There were no adverse reactions attributed to the Arthrella ointment.

These excellent beneficial actions of Arthrella ointment are because of its potent topical anti-inflammatory, analgesic and counter-irritant properties. Cinnamomum camphora, Oils of Gaultheria fragrantissima & Capsicum annum are counter-irritants and helps to relieve pain immediately. Eucalyptus globulus,[13,15] Vitex negundo are analgesic, anti-inflammatory medicines. [17] Arthrella ointment targets the peripheral nerves and soft tissue at pain site. The counter-irritants in Arthrella ointment also help the absorption of the anti-inflammatory ingredients through the skin. Thus, Arthrella ointment relieves pain immediately, reduces inflammation rapidly and restores mobility instantly.


In conclusion, this trial demonstrates the potential efficacy and safety of Arthrella ointment in the symptomatic treatment of OA pain over 4 weeks of therapy. The Arthrella ointment demonstrated better results with acute and chronic inflammatory pain experienced in chronic degenerative condition like osteoarthritis.


1. Felson DT. Epidemiology of hip and knee osteoartritis. Epidemiol Rev 1988;10: 1-28.

2. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60: 91-7.

3. Yelin E. The earnings, income, and assets of

persons aged 51-61 with and without musculoskeletal conditions. J Rheumatol 1997;24: 2024-30.

4. Wynne HA, Campell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmacoeconomics 1994;3: 107-23.

5. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95: 1681-90.

6. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8: 18-24.

7. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123: 241-9.

8. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998;51(suppl): 8-16.

9. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325: 624-7.

10. Trolamine salycylate cream in osteoarthritis of the knee. JAMA 1982;247: 1311-3.

11. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions - a review of the literature. Drugs 1998;56: 783-99.

12. Stephani Schmidt, MSc (Pharm), Topical treatments for musculoskeletal pain., SA Pharmacist’s Assistant [Winter 2016]

13. Tomohiko Kotaka, Shoji Kimura, Makoto Kashiwayanagi, Jun Iwamoto., Camphor induces cold and warm sensations with increases in skin and muscle blood flow in human., Biol Pharm Bull., 2014;37(12)

14. Yang Suk Jun, Purum Kang, Sun Seek Min, Jeong-Min Lee, Hyo-Keun Kim, and Geun Hee Seol., Effect of Eucalyptus Oil Inhalation on Pain and Inflammatory Responses after Total Knee Replacement: A Randomized Clinical Trial Evidence-Based Complementary and Alternative Medicine., Volume 2013, Article ID 502727, 7 pages.

15. Xue Zhang, Jialin Sun, Wenyu Xin, Yongjie Li, Lin Ni, Xiaowei Ma, Dan Zhang, Dongming Zhang, Tiantai Zhang, Guanhua Du., Anti-inflammation effect of methyl salicylate 2-O- β-D-lactoside on adjuvant induced-arthritis rats and lipopolysaccharide (LPS)-treated murine macrophages RAW264.7 cells., Int Immunopharmaco., 2015 Mar;25(1):88-95.

16. Katz JN, Arant KR, Loeser RF., Diagnosis and treatment of hip and knee osteoarthritis: A review. 2021;325:568–578

17. Killol S Chokshi, Jaimin S Suthar, Divyesh B Ladola, Pratha K Patel, Anupsinh J Solanki, Aditya J Purohit, Gaurav V Moradiya, Sandeep B Patel, Dhagla R Chaudhary, Kashyap K Bhatt & Dilip Jani., To Prepare Oil Containing Vitex Negundo Extract obtained through different Organic Solvents and evaluate its Anti-Inflammatory Activity by Topical Application., IOSR Journal of Pharmacy and Biological Sciences (IOSRJPBS) ISSN: 2278-3008 Volume 2, Issue 6 (Sep-Oct. 2012), PP 22-24